Segall Bryant & Hamill’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-10,298
| Closed | -$772K | – | 379 |
|
|
2023
Q3 | $772K | Buy |
10,298
+49
| +0.5% | +$3.77K | 0.01% | 457 |
|
|
2023
Q2 | $790K | Buy |
10,249
+1
| +0% | +$80 | 0.01% | 516 |
|
|
2023
Q1 | $850K | Sell |
10,248
-47
| -0.5% | -$3.89K | 0.01% | 508 |
|
|
2022
Q4 | $883K | Sell |
10,295
-92
| -0.9% | -$7.29K | 0.01% | 503 |
|
|
2022
Q3 | $641K | Buy |
10,387
+92
| +0.9% | +$5.8K | 0.01% | 542 |
|
|
2022
Q2 | $636K | Sell |
10,295
-26
| -0.3% | -$1.61K | 0.01% | 550 |
|
|
2022
Q1 | $615K | Sell |
10,321
-4,050
| -28% | -$259K | 0.01% | 572 |
|
|
2021
Q4 | $1.04M | Sell |
14,371
-239
| -2% | -$16.5K | 0.01% | 450 |
|
|
2021
Q3 | $1.02M | Buy |
14,610
+189
| +1% | +$13.3K | 0.01% | 527 |
|
|
2021
Q2 | $993K | Sell |
14,421
-14,876
| -51% | -$993K | 0.01% | 518 |
|
|
2021
Q1 | $1.89M | Buy |
29,297
+15,487
| +112% | +$999K | 0.02% | 476 |
|
|
2020
Q4 | $807K | Sell |
13,810
-379
| -3% | -$22.9K | 0.01% | 501 |
|
|
2020
Q3 | $897K | Sell |
14,189
-3,212
| -18% | -$223K | 0.01% | 468 |
|
|
2020
Q2 | $1.34M | Buy |
17,401
+1,418
| +9% | +$109K | 0.02% | 389 |
|
|
2020
Q1 | $1.2M | Sell |
15,983
-2,196
| -12% | -$152K | 0.02% | 417 |
|
|
2019
Q4 | $1.18M | Sell |
18,179
-40
| -0.2% | -$2.6K | 0.02% | 490 |
|
|
2019
Q3 | $1.16M | Hold |
18,219
| – | – | 0.02% | 495 |
|
|
2019
Q2 | $1.23M | Buy |
18,219
+2,256
| +14% | +$148K | 0.02% | 489 |
|
|
2019
Q1 | $1.04M | Sell |
15,963
-69
| -0.4% | -$4.59K | 0.02% | 525 |
|
|
2018
Q4 | $1M | Sell |
16,032
-181
| -1% | -$12.7K | 0.02% | 516 |
|
|
2018
Q3 | $1.25M | Sell |
16,213
-2,961
| -15% | -$224K | 0.02% | 514 |
|
|
2018
Q2 | $1.36M | Buy |
19,174
+5,447
| +40% | +$385K | 0.02% | 494 |
|
|
2018
Q1 | $1.03M | Sell |
13,727
-200
| -1% | -$15.9K | 0.02% | 352 |
|
|
2017
Q4 | $998K | Sell |
13,927
-6,551
| -32% | -$497K | 0.02% | 345 |
|
|
2017
Q3 | $1.66M | Sell |
20,478
-55,114
| -73% | -$4.21M | 0.04% | 317 |
|
|
2017
Q2 | $5.35M | Sell |
75,592
-22,835
| -23% | -$1.52M | 0.13% | 173 |
|
|
2017
Q1 | $6.68M | Sell |
98,427
-137,575
| -58% | -$9.67M | 0.16% | 138 |
|
|
2016
Q4 | $16.9M | Buy |
236,002
+4,194
| +2% | +$312K | 0.42% | 73 |
|
|
2016
Q3 | $18.3M | Buy |
231,808
+5,283
| +2% | +$429K | 0.47% | 62 |
|
|
2016
Q2 | $18.9M | Buy |
226,525
+25,369
| +13% | +$2.25M | 0.5% | 60 |
|
|
2016
Q1 | $18.5M | Buy |
201,156
+4,253
| +2% | +$384K | 0.46% | 64 |
|
|
2015
Q4 | $19.9M | Buy |
196,903
+492
| +0.3% | +$51.2K | 0.48% | 66 |
|
|
2015
Q3 | $19.3M | Buy |
196,411
+2,070
| +1% | +$230K | 0.47% | 69 |
|
|
2015
Q2 | $22.8M | Buy |
194,341
+24,217
| +14% | +$2.65M | 0.51% | 64 |
|
|
2015
Q1 | $16.7M | Buy |
170,124
+139,289
| +452% | +$14.1M | 0.38% | 87 |
|
|
2014
Q4 | $2.91M | Sell |
30,835
-820
| -3% | -$84.8K | 0.07% | 283 |
|
|
2014
Q3 | $3.37M | Sell |
31,655
-320
| -1% | -$31.3K | 0.08% | 252 |
|
|
2014
Q2 | $2.65M | Sell |
31,975
-5,470
| -15% | -$426K | 0.06% | 236 |
|
|
2014
Q1 | $2.65M | Buy |
37,445
+2,707
| +8% | +$212K | 0.06% | 247 |
|
|
2013
Q4 | $2.61M | Buy |
34,738
+41
| +0.1% | +$2.85K | 0.06% | 250 |
|
|
2013
Q3 | $2.18M | Buy |
34,697
+1,852
| +6% | +$111K | 0.05% | 261 |
|
|
2013
Q2 | $1.68M | Buy |
+32,845
| New | +$1.71M | 0.04% | 271 |
|
Other funds holding GILD
Segall Bryant & Hamill's GILD Position: Q4 2023 in Review
Segall Bryant & Hamill sold out of Gilead Sciences (GILD) in Q4 2023, closing a stake of 10,298 shares — an estimated $772K sold.
Segall Bryant & Hamill first reported a position in GILD in Q2 2013 and held it in 42 quarters. The position peaked at $22.8M in Q2 2015. 1,775 funds tracked by Wall St. Rank hold GILD as of Q4 2023.
- Segall Bryant & Hamill reported no remaining Gilead Sciences position as of Q4 2023 after selling out during the quarter.
- Segall Bryant & Hamill sold 10,298 Gilead Sciences shares in Q4 2023, an estimated $772K.
- Segall Bryant & Hamill first reported a position in Gilead Sciences in Q2 2013 and held it in 42 quarters.
- Segall Bryant & Hamill's Gilead Sciences position peaked at $22.8M in Q2 2015.
- 1,775 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2023.
Based on Segall Bryant & Hamill's 13F filing for Q4 2023, filed 14 Feb 2024.